



SolAeroMed Inc.  
Unit 2, 3535 Research Road NW  
Calgary, AB, Canada T2L 2K8  
[www.solaeromed.com](http://www.solaeromed.com)

## **Q4 2011 Corporate Update**

On behalf of our team within SolAeroMed, I hope this update finds you healthy and happy and interested in learning how your investment in our company is developing. In the coming months we endeavor to keep our investors and partners informed of developments through our web site at [www.solaeromed.com](http://www.solaeromed.com).

The number of investors in SolAeroMed increased on Oct 28<sup>th</sup> as we successfully closed a round of friendly investment that met our target. This allows the SolAeroMed team to face 2012 with increased momentum and a comfortable financial position with which to drive planned short and medium term developments.

Our work over Q4 2011 included:

- Securing supply of cGMP drug for regulatory testing
- Addition of a regulatory and toxicology expert, Dr Colin Rousseaux, to lead our submission to Health Canada to begin the engagement process leading up to regulatory approval of clinical trials.
- Expanded management board to include well-established pharma business expertise with the addition of Dr Gwyn Humphries and Mr Ian McAffer to our board of directors.
- Expanded our non-dilutive funding with further grants including \$77,269 grant from CIHR focused on Knowledge Translation.
- Worked to develop our patent position by progressing discussions with the US patent office towards granting of a US patent. In addition, we have attracted interest from research colleagues working in related areas who have expressed interest in adding their patents to the SolAeroMed portfolio.

Our planned work through early 2012 includes:

- Submit a package to Health Canada regulators in order to organize an advisory meeting in Q1 2012. This meeting will help define our toxicology program that is required before any clinical trials in humans can be undertaken.

- Purchase of cGMP drug supply for use in toxicology work required by regulators.
- Negotiation with contract labs to carry out toxicology work
- Securing of additional non-dilutive funding (i.e. grants)
- Dissemination of the commercial potential of our technology to prospective pharmaceutical partners and investors.
- Development of the SolAeroMed web site to provide a clear and timely window on developments and news within SolAeroMed.

On behalf of SolAeroMed, I thank you for your interest and support for our company. We continue to work to ensure the commercial and scientific success of SolAeroMed. It is my intention to provide brief snapshots of our company to you through updates on a quarterly basis. This method, along with our website communication, should help keep you informed of developments. I and other members of the SolAeroMed team will be available as needed by email or phone.

We are planning our first Annual General Meeting of shareholders in early April 2012 and will be confirming details of date and venue early in the New Year. This AGM will include official business required of a company but will also provide an opportunity to present a summary of the latest developments of our technology and business plan and to meet with the SolAeroMed team and other shareholders.

Sincerely

Dr John Dennis, CEO  
Email: [info@solaeromed.com](mailto:info@solaeromed.com)